NEW YORK (GenomeWeb) – NanoString Technologies announced today that it has signed a collaboration agreement with Merck to develop a companion diagnostic to the pharmaceutical company's anti-PD-1 cancer therapy Keytruda (pembrolizumab).
Registering provides access to this and other free content.
Already have an account?Login Now.
Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.
Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.
In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.
Iceland has nearly eliminated Down syndrome from its population, CBS News reports.